AIO-Studien-gGmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 2007-01-01

Employees: 11

Market Cap: -

Website: http://www.aio-studien-ggmbh.de

Clinical Trials

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

Phase 2

Completed

Conditions: Her2-negative Metastatic Breast Cancer
Her2-negative Locally Advanced Breast Cancer

Interventions: Drug: Vinorebine, Everolimus
Drug: Vinorelbine

First Posted Date: 2012-01-27

Last Posted Date: 2017-08-09

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 139

Registration Number: NCT01520103

Locations: 🇩🇪
Hämatologisch-onkologische Gemeinschaftspraxis, Münster, Münster, Germany

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Phase 2

Completed

Conditions: Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

Interventions: Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel
Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel

First Posted Date: 2012-01-05

Last Posted Date: 2018-01-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 42

Registration Number: NCT01504256

Locations: 🇩🇪
Prof. Dr. F. Lordick, Leipzig, Germany

Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Adenocarcinoma of the Stomach

Interventions: Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab
Drug: Post-operative treatment trastuzumab mono therapy

First Posted Date: 2011-11-16

Last Posted Date: 2017-06-19

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 53

Registration Number: NCT01472029

Locations: 🇩🇪
Tagestherapiezentrum am ITM & III. Medizinische Klinik Universitätsmedizin Mannheim, Mannheim, Germany

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: FOLFOXIRI + Panitumumab
Drug: FOLFOXIRI

First Posted Date: 2011-04-04

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 93

Registration Number: NCT01328171

Locations: 🇩🇪
St. Vincenz-Krankenhaus, Paderborn, Nordrhein-Westfalen, Germany
🇩🇪
Klinikum Ludwigsburg, Ludwigsburg, Baden-Württemberg, Germany
🇩🇪
Klinikum der J.W. Goethe-Universität Frankfurt, Frankfurt, Hessen, Germany

and more 16 locations

ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction

Phase 2

Completed

Conditions: Stomach Neoplasms
Gastroesophageal Junction Neoplasms

Interventions: Drug: Epirubicin, Cisplatin, Capecitabine, Panitumumab
Drug: Epirubicin, Cisplatin, Capecitabine

First Posted Date: 2010-11-04

Last Posted Date: 2018-01-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 171

Registration Number: NCT01234324

Locations: 🇩🇪
AIO-Studien gGmbH, Berlin, Germany

Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers

Phase 2

Completed

Conditions: Gastrointestinal Cancers
Malignant Ascites

Interventions: Other: Placebo
Drug: Bevacizumab

First Posted Date: 2010-09-13

Last Posted Date: 2015-04-13

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 53

Registration Number: NCT01200121

Locations: 🇩🇪
Klinikum Leverkusen gGmbH, Medizinische Klinik III, Leverkusen, Nordrhein-Westfalen, Germany
🇩🇪
Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus, Hämatologie/Onkologie/Gastroonkologie, Mönchengladbach, Nordrhein-Westfalen, Germany
🇩🇪
Johannes Gutenberg Universität, Universitätsklinikum, I. Medizinische Klinik und Poliklinik, Mainz, Rheinland-Pfalz, Germany

and more 23 locations

Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

First Posted Date: 2009-09-09

Last Posted Date: 2015-09-01

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 853

Registration Number: NCT00973609

Locations: 🇩🇪
AIO-Studien gGmbH, Berlin, Germany

Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: Oxaliplatin, Capecitabine, Panitumumab
Drug: Oxaliplatin, Capecitabine

First Posted Date: 2009-08-03

Last Posted Date: 2013-03-04

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 9

Registration Number: NCT00950820

Locations: 🇩🇪
AIO-Studien-gGmbH, Berlin, Germany

Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: Placebo
Drug: Sorafenib
Drug: Oxaliplatin or Irinotecan
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2009-04-28

Last Posted Date: 2013-03-04

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 101

Registration Number: NCT00889343

Locations: 🇩🇪
Friedrich-Ebert-Krankenhaus Neumünster, Klinik für Hämatologie, Onkologie und Nephrologie, Neumünster, Schleswig-Holstein, Germany
🇩🇪
Hämatologisch-onkologische Praxis Dr. med. Peter Schmidt, Neunkirchen, Saarland, Germany
🇩🇪
Medizinisches Versorgungszentrum am Siloah St. Trudpert Klinikum, Pforzheim, Baden-Würtemberg, Germany

and more 53 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy